Skip to main content
main-content

Sodium-glucose co-transporter-2 inhibitors

News

08-09-2017 | Sodium-glucose co-transporter-2 inhibitors | News

Support for cardioprotective effects of SGLT2 inhibitors

Patients with type 2 diabetes receiving treatment with sodium-glucose co-transporter-2 inhibitors have a lower risk for adverse cardiovascular outcomes than those using other glucose-lowering drugs, results from the CVD-REAL Nordic study suggest.

08-03-2017 | Ipragliflozin | News

Ipragliflozin and pioglitazone ‘equally beneficial’ for type 2 diabetes with NAFLD

Results of a randomized trial suggest that the sodium-glucose cotransporter 2 inhibitor ipragliflozin has equivalent efficacy to pioglitazone for the treatment of patients with type 2 diabetes complicated by nonalcoholic fatty liver disease.

08-01-2017 | Canagliflozin | News

Cardiac biomarker data support canagliflozin cardioprotective effect

Treatment with canagliflozin has positive effects on biomarkers of cardiovascular disease risk in older patients with type 2 diabetes, research shows.

Read more

Related topics

Superior

Related

Specific

Opinion

01-13-2017 | Cardiovascular outcomes | Editorial | Article

Clinical implications of cardiovascular outcomes trials in type 2 diabetes

What do the results of CVOTs mean for practicing clinicians? Editorial board member Carol Hatch Wysham reviews the latest evidence and guidelines for reducing CV risk in patients with type 2 diabetes.

Original research

11-01-2016 | Type 2 diabetes | OriginalPaper | Article

Implications of the EMPA-REG Trial for Clinical Care and Research

An expert review of the EMPA-REG trial’s main findings, mechanisms that could explain its results, suggestions for ways in which clinical care may be influenced, and directions for future research.

Stamatouli AM & Inzucchi SE. Curr Diab Rep 2016;16:131. doi:10.1007/s11892-016-0822-7

09-30-2016 | Type 2 diabetes | Article

Combination therapy with glucagon-like peptide-1 analogues and sodium-glucose cotransporter-2 inhibitors in the management of diabesity: the real world experience

Results from this retrospective cohort study show that combination therapy of glucagon-like peptide-1 (GLP-1) agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors is a promising option for patients with diabesity.

Deol H et al. Endocrine 2017;55:173–178. doi:10.1007/s12020-016-1125-0

Journal articles and book chapters

05-14-2017 | Obesity | Review | Article

Medication use for the treatment of diabetes in obese individuals

In this review, Wilding discusses the main pharmacological approaches that can be used to support weight loss in individuals with diabetes.

Wilding JPH. Diabetologia 2017. doi:10.1007/s00125-017-4288-1

02-02-2017 | Cardiovascular outcomes | Review | Article

Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes

Many of the currently available oral anti-diabetic agents have clinically relevant cardiovascular effects. This expert review concludes that optimal approach to the reduction of cardiovascular risk in diabetic patients should focus on aggressive management of the standard cardiovascular risk factors rather than purely on intensive glycemic control.

Xu J & Rajaratnam R. Cardiovasc Diabetol 2017;16:18. doi:10.1186/s12933-017-0499-5

01-26-2017 | Hypertension | Review | Article

Blood pressure control in type 2 diabetic patients

What is the best method for controlling hypertension in patients with diabetes, and what should be the goal? This review takes a look at the evidence and guidelines supporting different BP targets, and provides an overview of the available treatment options, including the new classes of anti-diabetic drugs.

Grossman A & Grossman E. Cardiovasc Diabetol 2017;16:3. doi:10.1186/s12933-016-0485-3

Case reports

04-26-2016 | Neonatal diabetes | Case study | Article

Not all diabetes in infants is type 1: A case report

The authors present their experience with a patient with permanent neonatal diabetes, initially misdiagnosed as type 1 diabetes, who was successfully transitioned to oral sulfonylurea therapy after 37 years of insulin dependence.

Arce KM & Pantalone KM. Diabetes Ther 2016; 7: 369–375. doi:10.1007/s13300-016-0171-1

image credits